Cargando…
AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
BACKGROUND: Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs. METHODS: Patients...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792827/ http://dx.doi.org/10.21037/med-22-ab002 |
_version_ | 1784859718760529920 |
---|---|
author | Wang, Chang-Lu Zhao, Yi-Zhuo Zhang, Qin Zeng, Wan-Qin Jia, Tian-Ying Zhu, Lei Fang, Wen-Tao Fu, Xiao-Long |
author_facet | Wang, Chang-Lu Zhao, Yi-Zhuo Zhang, Qin Zeng, Wan-Qin Jia, Tian-Ying Zhu, Lei Fang, Wen-Tao Fu, Xiao-Long |
author_sort | Wang, Chang-Lu |
collection | PubMed |
description | BACKGROUND: Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs. METHODS: Patients with progression disease after failure of platinum-based chemotherapy were enrolled in this study. Anlotinib was orally taken once a day at an initial dose of 12 mg (10 mg when body weight <60 kg). The cycle was repeated every 3 weeks (2 weeks of treatment followed by 1 week rest). There are 3 dose levels (12, 10 and 8 mg), and dose may be reduced to a lower level when grade 3 toxicity occurred. Objective response rate (ORR) and progression-free survival (PFS) were recorded as primary end points, and they were analyzed separately in thymoma (THY) and thymic carcinoma (TC) cohorts. Meanwhile, toxicities were assessed according to CTCAE (version 5.0). RESULTS: There were 50 patients enrolled in this study from October 2018 to June 2021 at a median age of 50 (range, 23–79) years old. Patients with THY and TC were 33 (66%) and 17 (34%) respectively. The ORR in THY and TC patients were 33% (11/33) and 41% (7/17), respectively. The median PFS (mPFS) were 7 (95% CI: 5.9–10.2) months in THY patients and 6 (95% CI: 4.6–9.3) months in TC group. Eleven patients experienced dose reduction due to toxicities, among whom, 8 patients discontinued treatment even after dose reduction. Six patients with THY showed myasthenia gravis (MG) deterioration during treatment, and 2 of them died of MG crisis. CONCLUSIONS: Anlotinib is active in patients with advanced TETs refractory to routine chemotherapy. Prescription of Anlotinib to patients with MG should be made cautiously. |
format | Online Article Text |
id | pubmed-9792827 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-97928272022-12-30 AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors Wang, Chang-Lu Zhao, Yi-Zhuo Zhang, Qin Zeng, Wan-Qin Jia, Tian-Ying Zhu, Lei Fang, Wen-Tao Fu, Xiao-Long Mediastinum Abstract BACKGROUND: Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs. METHODS: Patients with progression disease after failure of platinum-based chemotherapy were enrolled in this study. Anlotinib was orally taken once a day at an initial dose of 12 mg (10 mg when body weight <60 kg). The cycle was repeated every 3 weeks (2 weeks of treatment followed by 1 week rest). There are 3 dose levels (12, 10 and 8 mg), and dose may be reduced to a lower level when grade 3 toxicity occurred. Objective response rate (ORR) and progression-free survival (PFS) were recorded as primary end points, and they were analyzed separately in thymoma (THY) and thymic carcinoma (TC) cohorts. Meanwhile, toxicities were assessed according to CTCAE (version 5.0). RESULTS: There were 50 patients enrolled in this study from October 2018 to June 2021 at a median age of 50 (range, 23–79) years old. Patients with THY and TC were 33 (66%) and 17 (34%) respectively. The ORR in THY and TC patients were 33% (11/33) and 41% (7/17), respectively. The median PFS (mPFS) were 7 (95% CI: 5.9–10.2) months in THY patients and 6 (95% CI: 4.6–9.3) months in TC group. Eleven patients experienced dose reduction due to toxicities, among whom, 8 patients discontinued treatment even after dose reduction. Six patients with THY showed myasthenia gravis (MG) deterioration during treatment, and 2 of them died of MG crisis. CONCLUSIONS: Anlotinib is active in patients with advanced TETs refractory to routine chemotherapy. Prescription of Anlotinib to patients with MG should be made cautiously. AME Publishing Company 2022-12-30 /pmc/articles/PMC9792827/ http://dx.doi.org/10.21037/med-22-ab002 Text en 2022 Mediastinum. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Abstract Wang, Chang-Lu Zhao, Yi-Zhuo Zhang, Qin Zeng, Wan-Qin Jia, Tian-Ying Zhu, Lei Fang, Wen-Tao Fu, Xiao-Long AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors |
title | AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors |
title_full | AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors |
title_fullStr | AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors |
title_full_unstemmed | AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors |
title_short | AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors |
title_sort | ab002. anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792827/ http://dx.doi.org/10.21037/med-22-ab002 |
work_keys_str_mv | AT wangchanglu ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors AT zhaoyizhuo ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors AT zhangqin ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors AT zengwanqin ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors AT jiatianying ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors AT zhulei ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors AT fangwentao ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors AT fuxiaolong ab002anlotinibassalvagetreatmentforpatientswithrelapsedandrefractorythymicepithelialtumors |